Evotec on target for revenue aims with Vifor deal
This article was originally published in Scrip
Executive Summary
Evotec and Vifor Pharma are to collaborate on the discovery of a preclinical candidate for the treatment of anaemia. The deal boosts Evotec's chances of reaching its revenue target of €60 million by 2012.